==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1027 which contains 5 entries.


Entry 1
(1) Primary information
ID1205
ThPP IDTh1027
Therapeutic Peptide/Protein NameInsulin Regular
SequenceA-chain:GIVEQCCTSICSLYQLENYCN B-chain:FVNQHLCGSHLV view full sequnce in fasta
Functional ClassificationIa
Molecular Weight5.808
Chemical FormulaC257H383N65O77S6
Isoelectric Point5.39
Hydrophobicity0.218
Melting Point (℃)81
Half LifeN.A.
DescriptionInsulin regular is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use.
Indication/DiseaseIndicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus.
PharmacodynamicsInsulin regular is a short-acting insulin. When subcutaneously administered, the onset of action (as evidenced by a decrease in glucose level) occurs 30 minutes post-dose. Maximal effect occurs between 1.5 and 3.5 hours post-dose. The glucose-lowering effect occurs 8 hours post-dose. Compared to other rapid-acting insulin analogs, insulin regular has a slower onset of action and longer duration of action.
Mechanism of ActionThe primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver. Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.
ToxicityHypoglycemia is caused due to insulin toxicity.
MetabolismPredominantly cleared by metabolic degradation via a receptor-mediated process.
AbsorptionGenerally well absorbed.
Volume of Distribution0.15 L/kg
ClearanceN.A.
CategoriesAntidiabetic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionLiraglutide's coadministration may increase the risk of hypoglycemia. A lower dose of the antidiabetic agent may be needed.
TargetInsulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r
Information of corresponding available drug in the market
Brand NameHumulin R
CompanyEli Lilly and Company
Brand DiscriptionHumulin R(insulin human recombinant) U-100 is a polypeptide hormone structurally identical to human insulin synthesized through rDNA technology in a special non-disease producing laboratory strain of Escherichia coli bacteria.
Prescribed forTreating diabetes mellitus.
Chemical NameN.A.
FormulationIt contains human insulin (rDNA origin) 100 units/mL, glycerin 16 mg/mL and metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 units) and water for injection. The pH is 7.0 to 7.8. Sodiumhydroxide and/or hydrochloric acid may be added durin
Physcial AppearanceSterile, clear, aqueous, and colorless solution
Route of AdministrationSubcutaneous Injection in the abdominal wall, the
Recommended DosageHumulin R (insulin (human recombinant)) U-100, when used subcutaneously, is usually given three or more times daily before meals. The average range of total daily insulin requirement for maintenance therapy in insulin-treated patients without severe insulin resistance lies between 0.5 and 1 unit/kg/day.
ContraindicationDuring episodes of hypoglycemia and in patients hypersensitive to humulin R.
Side EffectsRash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; wheezing; muscle pain; changes in vision; chills; confusion; dizziness; drowsiness; fainting; fast or irregular heartbeat; headache; loss of apetite.
Useful Linkhttp://www.drugs.com/cdi/humulin-r.html
PubMed ID22960692
3-D StructureTh1027 (View) or (Download)


Entry 2
(2) Primary information
ID1206
ThPP IDTh1027
Therapeutic Peptide/Protein NameInsulin Regular
SequenceA-chain:GIVEQCCTSICSLYQLENYCN, B-chain:FVNQHLCGSHL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight5.808
Chemical FormulaC257H383N65O77S6
Isoelectric Point5.39
Hydrophobicity0.218
Melting Point (℃)81
Half LifeN.A.
DescriptionInsulin regular is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use.
Indication/DiseaseIndicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus.
PharmacodynamicsInsulin regular is a short-acting insulin. When subcutaneously administered, the onset of action (as evidenced by a decrease in glucose level) occurs 30 minutes post-dose. Maximal effect occurs between 1.5 and 3.5 hours post-dose. The glucose-lowering effect occurs 8 hours post-dose. Compared to other rapid-acting insulin analogs, insulin regular has a slower onset of action and longer duration of action.
Mechanism of ActionThe primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver. Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.
ToxicityHypoglycemia is caused due to insulin toxicity.
MetabolismPredominantly cleared by metabolic degradation via a receptor-mediated process.
AbsorptionGenerally well absorbed.
Volume of Distribution0.15 L/kg
ClearanceN.A.
CategoriesAntidiabetic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.rxlist.com/humulin-r-drug.htm
PubMed ID22960692
3-D StructureTh1027 (View) or (Download)


Entry 3
(3) Primary information
ID1207
ThPP IDTh1027
Therapeutic Peptide/Protein NameInsulin Regular
SequenceA-chain:GIVEQCCTSICSLYQLENYCN, B-chain:FVNQHLCGSHL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight5.808
Chemical FormulaC257H383N65O77S6
Isoelectric Point5.39
Hydrophobicity0.218
Melting Point (℃)81
Half LifeN.A.
DescriptionInsulin regular is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use.
Indication/DiseaseIndicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus.
PharmacodynamicsInsulin regular is a short-acting insulin. When subcutaneously administered, the onset of action (as evidenced by a decrease in glucose level) occurs 30 minutes post-dose. Maximal effect occurs between 1.5 and 3.5 hours post-dose. The glucose-lowering effect occurs 8 hours post-dose. Compared to other rapid-acting insulin analogs, insulin regular has a slower onset of action and longer duration of action.
Mechanism of ActionThe primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver. Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.
ToxicityHypoglycemia is caused due to insulin toxicity.
MetabolismPredominantly cleared by metabolic degradation via a receptor-mediated process.
AbsorptionGenerally well absorbed.
Volume of Distribution0.15 L/kg
ClearanceN.A.
CategoriesAntidiabetic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.ncbi.nlm.nih.gov/pubmed/23512415
PubMed ID22960692
3-D StructureTh1027 (View) or (Download)


Entry 4
(4) Primary information
ID1208
ThPP IDTh1027
Therapeutic Peptide/Protein NameInsulin Regular
SequenceA-chain:GIVEQCCTSICSLYQLENYCN, B-chain:FVNQHLCGSHL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight5.808
Chemical FormulaC257H383N65O77S6
Isoelectric Point5.39
Hydrophobicity0.218
Melting Point (℃)81
Half LifeN.A.
DescriptionInsulin regular is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use.
Indication/DiseaseIndicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus.
PharmacodynamicsInsulin regular is a short-acting insulin. When subcutaneously administered, the onset of action (as evidenced by a decrease in glucose level) occurs 30 minutes post-dose. Maximal effect occurs between 1.5 and 3.5 hours post-dose. The glucose-lowering effect occurs 8 hours post-dose. Compared to other rapid-acting insulin analogs, insulin regular has a slower onset of action and longer duration of action.
Mechanism of ActionThe primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver. Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.
ToxicityHypoglycemia is caused due to insulin toxicity.
MetabolismPredominantly cleared by metabolic degradation via a receptor-mediated process.
AbsorptionGenerally well absorbed.
Volume of Distribution0.15 L/kg
ClearanceN.A.
CategoriesAntidiabetic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameNovolin R
CompanyNovo Nordisk
Brand DiscriptionNovolin R is a polypeptide hormone structurally identical to native human insulin and is produced by recombinant DNA technology, utilizing Saccharomyces cerevisiae(baker's yeast) as the production organism.
Prescribed forUsed for the treatment of patients with diabetes mellitus, for the control of hyperglycemia
Chemical NameN.A.
FormulationIt contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH is adjusted to 7.4. Hydrochloric acid 2N or sodium hydroxide 2N may be added to adjust pH. No
Physcial AppearanceSterile, clear, aqueous, and colorless solution
Route of AdministrationSubcutaneous and Intravenous infusion
Recommended DosageThe injection of Novolin R (recombinant dna origin) should be followed by a meal within approximately 30 minutes of administration The average range of total daily insulin requirement for maintenance therapy in insulin-treated patients lies between 0.5 and 1.0 IU/kg.
ContraindicationDuring episodes of hypoglycemia and in patients with hypersensitivity to Novolin R
Side EffectsHypoglycemia, or low blood sugar, is the most common side effect. Symptoms include headache, hunger, dizziness, sweating, irritability, trouble concentrating, rapid breathing, fast heartbeat, fainting, or seizure (severe hypoglycemia can be fatal).
Useful Linkhttp://www.rxlist.com/novolin-r-drug.htm
PubMed ID22960692
3-D StructureTh1027 (View) or (Download)


Entry 5
(5) Primary information
ID1209
ThPP IDTh1027
Therapeutic Peptide/Protein NameInsulin Regular
SequenceA-chain:GIVEQCCTSICSLYQLENYCN, B-chain:FVNQHLCGSHL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight5.808
Chemical FormulaC257H383N65O77S6
Isoelectric Point5.39
Hydrophobicity0.218
Melting Point (℃)81
Half LifeN.A.
DescriptionInsulin regular is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use.
Indication/DiseaseIndicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus.
PharmacodynamicsInsulin regular is a short-acting insulin. When subcutaneously administered, the onset of action (as evidenced by a decrease in glucose level) occurs 30 minutes post-dose. Maximal effect occurs between 1.5 and 3.5 hours post-dose. The glucose-lowering effect occurs 8 hours post-dose. Compared to other rapid-acting insulin analogs, insulin regular has a slower onset of action and longer duration of action.
Mechanism of ActionThe primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver. Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.
ToxicityHypoglycemia is caused due to insulin toxicity.
MetabolismPredominantly cleared by metabolic degradation via a receptor-mediated process.
AbsorptionGenerally well absorbed.
Volume of Distribution0.15 L/kg
ClearanceN.A.
CategoriesAntidiabetic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.drugs.com/mtm/novolin-r.html
PubMed ID22960692
3-D StructureTh1027 (View) or (Download)